PUMA BIOTECHNOLOGY, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value
PUMA BIOTECHNOLOGY, INC. (PBYI) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value of $3.75 per share for the 9-month period ending 2024-09-30, per its 10-Q filed 2024-11-07.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue · last filed 2024-11-07
- PUMA BIOTECHNOLOGY, INC. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for the quarter ending 2024-03-31 was $3.71, a 20.22% decline year-over-year.
- PUMA BIOTECHNOLOGY, INC. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for the quarter ending 2023-03-31 was $4.65, a 44.84% decline year-over-year.
- PUMA BIOTECHNOLOGY, INC. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for the quarter ending 2022-03-31 was $8.43, a 12.73% decline year-over-year.
- PUMA BIOTECHNOLOGY, INC. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for the quarter ending 2021-03-31 was $9.66, a 67.38% decline year-over-year.
- PUMA BIOTECHNOLOGY, INC. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for fiscal 2023 was $4.15, a 37.22% decline from fiscal 2022.
- PUMA BIOTECHNOLOGY, INC. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for fiscal 2022 was $6.61, a 30.49% decline from fiscal 2021.
- PUMA BIOTECHNOLOGY, INC. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for fiscal 2021 was $9.51, a 62.81% decline from fiscal 2020.
- PUMA BIOTECHNOLOGY, INC. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for fiscal 2020 was $25.57, a 23.81% decline from fiscal 2019.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|---|
| 2024-09-30 | $3.75 10-Q · filed 2024-11-07 | |||
| 2024-06-30 | $3.75 10-Q · filed 2024-08-01 | |||
| 2024-03-31 | $3.71 10-Q · filed 2024-05-02 | |||
| 2023-12-31 | $4.15 10-K · filed 2024-02-29 | |||
| 2023-09-30 | $4.12 10-Q · filed 2023-11-02 | |||
| 2023-06-30 | $4.85 10-Q · filed 2023-08-03 | |||
| 2023-03-31 | $4.65 10-Q · filed 2023-05-04 | |||
| 2022-12-31 | $6.61 10-K · filed 2024-02-29 | |||
| 2022-09-30 | $6.51 10-Q · filed 2022-11-03 | |||
| 2022-06-30 | $8.14 10-Q · filed 2022-08-04 | |||
| 2022-03-31 | $8.43 10-Q · filed 2022-05-05 | |||
| 2021-12-31 | $9.51 10-K · filed 2023-03-02 | |||
| 2021-09-30 | $9.52 10-Q · filed 2021-11-04 | |||
| 2021-06-30 | $9.65 10-Q · filed 2021-08-05 | |||
| 2021-03-31 | $9.66 10-Q · filed 2021-05-06 | |||
| 2020-12-31 | $25.57 10-K · filed 2022-03-03 | |||
| 2020-09-30 | $34.03 10-Q · filed 2020-11-05 | |||
| 2020-06-30 | $32.46 10-Q · filed 2020-08-06 | |||
| 2020-03-31 | $29.61 10-Q · filed 2020-05-07 | |||
| 2019-12-31 | $33.56 10-K · filed 2021-03-01 | |||
| 2019-09-30 | $35.13 10-Q · filed 2019-11-07 | |||
| 2019-06-30 | $35.83 10-Q · filed 2019-08-09 | |||
| 2019-03-31 | $38.23 10-Q · filed 2019-05-10 | |||
| 2018-12-31 | $36.81 10-K · filed 2020-02-28 | |||
| 2018-09-30 | $37.90 10-Q · filed 2018-11-05 | |||
| 2018-06-30 | $38.95 10-Q · filed 2018-08-09 | |||
| 2018-03-31 | $38.79 10-Q · filed 2018-05-10 | |||
| 2017-12-31 | $59.76 10-K · filed 2019-03-01 | |||
| 2017-09-30 | $61.53 10-Q · filed 2017-11-09 | |||
| 2017-06-30 | $73.74 10-Q · filed 2017-08-09 | |||
| 2017-03-31 | $72.27 10-Q · filed 2017-05-10 | |||
| 2016-12-31 | $77.69 10-K · filed 2018-03-09 | |||
| 2016-09-30 | $85.08 10-Q · filed 2016-11-09 | |||
| 2016-06-30 | $95.66 10-Q · filed 2016-08-09 | |||
| 2016-03-31 | $95.25 10-Q · filed 2016-05-10 | |||
| 2015-12-31 | $69.41 10-K · filed 2016-02-29 | |||
| 2015-09-30 | $61.22 10-Q · filed 2015-11-09 | |||
| 2015-06-30 | $44.21 10-Q · filed 2015-08-10 | |||
| 2015-03-31 | $44.13 10-Q · filed 2015-05-11 | |||
| 2014-12-31 | $17.85 10-K · filed 2015-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |